… on the entire spectrum of NAFLD including fibrosis. In this study, we tested this hypothesis
by silencing Pnpla3 in vivo using a liver-targeted ASO treatment in Pnpla3 I148M knock-in …

… emerging oligonucleotide drugs (eg antisense oligonucleotide, … and Scd inhibitors were
reported to ameliorate NASH 159 by … , the overexpression of Pnpla3 I148M in NAFLD 639 mouse …

… Of these modalities, RNAi (using small interfering RNAs (siRNAs)) and antisense oligonucleotides
(ASOs) are currently being employed therapeutically or are in clinical studies for the …

… diseases such as nonalcoholic fatty liver disease (NAFLD), … in hepatic STK25 levels and
amelioration liver steatosis, … of several molecular targets such as PNPLA3, HSP 47, AAT, TTR, …

… 3 (PNPLA3) with nonalcoholic fatty liver disease (NAFLD); the … A nonallele selective PNPLA3
antisense oligonucleotide (… to PNPLA3 I148M and its therapeutic effects in ameliorating …

… Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose …
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis …

… PNPLA3 variation predisposing to fatty liver disease on the biological functions of the …
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis …

… Nonalcoholic fatty liver disease (NAFLD) refers to a spectrum of histological abnormalities
in the liver, ranging from … Genetic variation in PNPLA3 confers susceptibility to nonalcoholic …

… , PNPLA3 I148M overexpression accelerated steatohepatitis … Silencing PNPLA3 I148M
after its initial overexpression … ), especially its aggressive variant nonalcoholic steatohepatitis (…

… outcome (nonalcoholic steatohepatitis, cirrhosis) in NAFLD, … PNPLA3 148M knockin mice
[17]; it benefited from silencing … The mechanism of GLP-1RAs ameliorating hepatic steatosis …